Effect of ethyl icosapentate on urinary calcium and oxalate excretion

Background: The effect of ethyl icosapentate (EPA‐E) on urinary calcium and oxalic acid excretion was examined to evaluate whether EPA‐E is useful in the prevention of calcium‐containing urinary stones. Methods: For 6 months, urine was measured daily from 40 calcium‐containing urinary stone producer...

Full description

Saved in:
Bibliographic Details
Published in:International journal of urology 2000-10, Vol.7 (10), p.361-365
Main Authors: Konya, Eiji, Tsuji, Hidenori, Umekawa, Tohru, Kurita, Takashi, Iguchi, Masanori
Format: Article
Language:English
Subjects:
Adult
Aged
Blood Urea Nitrogen
Calcium - urine
calcium-containing urinary stone
Cholesterol - blood
Creatine - urine
Eicosapentaenoic Acid - analogs & derivatives
Eicosapentaenoic Acid - therapeutic use
ethyl icosapentate (EPA-E)
Female
Humans
hypercalciuria
Magnesium - urine
Male
Middle Aged
Oxalic Acid - urine
Triglycerides - blood
Uric Acid - urine
Urinary Calculi - blood
Urinary Calculi - drug therapy
Urinary Calculi - urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The effect of ethyl icosapentate (EPA‐E) on urinary calcium and oxalic acid excretion was examined to evaluate whether EPA‐E is useful in the prevention of calcium‐containing urinary stones. Methods: For 6 months, urine was measured daily from 40 calcium‐containing urinary stone producers at an outpatient clinic, before and after the administration of 1800 mg/day EPA‐E. The urine was measured for volume, urea nitrogen, creatinine, calcium, magnesium, phosphorus, uric acid, oxalic acid and citric acid. Serum total cholesterol and triglyceride were also measured. Results: Urinary calcium excretion was not reduced in any of the patients or particular hypercalciuric groups, nor did the level of calcium change. However, nine of the 25 hypercalciuric patients experienced a significant urinary calcium reduction to the normal calciuric level (a reduction of approximately 44%). It is not known why these particular patients experienced a reduction. Urinary oxalic acid did not change, whether hypercalciuria was present or not. Conclusions: These findings suggest that EPA‐E is not particularly effective in reducing urinary calcium excretion in the hypercalciuric patients, but it needs future investigation because some patients experienced significant urinary calcium reduction.
ISSN:0919-8172
1442-2042
DOI:10.1046/j.1442-2042.2000.00211.x